Reasons to Retain STE Stock in Your Portfolio for Now
STERIS plc (STE) is recommended for retention due to its strong Healthcare and Applied Sterilization Technologies (AST) segments, which show robust market adoption and service revenue growth, respectively. Despite macroeconomic volatilities and foreign exchange risks, the company's positive financial outlook, including an earnings yield above its industry average, suggests it can navigate these challenges. Analysts project a 0.4% increase in EPS for fiscal 2027 and a 7.4% growth in revenues, indicating continued financial health.
Steris stock (IE00BFY8C754): Piper Sandler reaffirms Overweight after earnings
Piper Sandler has reiterated an "Overweight" rating and a $270 target price for Steris (IE00BFY8C754) after the company reported earnings that exceeded revenue forecasts. While revenue came in slightly above estimates at $1.6 billion, adjusted EPS of $2.83 missed the $2.85 expectation. The stock is considered relevant for US investors due to its NYSE listing and exposure to the healthcare infrastructure market, which can be attractive during market volatility.
Steris PLC stock outperforms competitors on strong trading day
Shares of Steris PLC (STE) rose 1.71% to $219.67 on Thursday, marking its fourth consecutive day of gains. This performance outpaced the broader market, with the S&P 500 Index rising 0.17% and the Dow Jones Industrial Average rising 0.55% on the same trading day.
Piper Sandler reiterates Overweight on Steris stock at $270 target
Piper Sandler has reiterated an Overweight rating and a $270 price target on Steris (NYSE:STE), noting the stock appears undervalued with potential upside. The company's recent fourth-quarter earnings saw a slight miss, but EPS guidance exceeded expectations, and longer-term healthcare guidance was raised. Steris demonstrates strong financial health, consistent dividend increases for 15 years, and plans for increased share buybacks.
STERIS plc $STE Stock Holdings Boosted by Handelsbanken Fonder AB
Handelsbanken Fonder AB significantly increased its stake in STERIS plc (NYSE:STE) during the fourth quarter, now holding 74,445 shares valued at approximately $18.9 million. This comes as STERIS reported quarterly earnings of $2.83 per share, slightly below estimates, on revenues of $1.59 billion. Analysts currently maintain a "Moderate Buy" rating for the stock with an average price target of $275.67.
Steris stock (IE00BFY8C754): steady after latest quarterly results and acquisition push
Steris stock remains under scrutiny following its latest quarterly results and continued integration of recent acquisitions, particularly Cantel Medical. Investors are monitoring margins, demand from hospitals and pharmaceutical companies, and the impact of rising costs on future guidance. The company, which specializes in infection prevention and sterilization, navigates growth opportunities and cost pressures in its core markets.
Steris plc stock (IE00BFY8C754): earnings momentum and NYSE move put infection prevention specialist
Steris plc reported higher revenue and adjusted earnings for fiscal 2025, keeping the infection prevention specialist on the radar of US healthcare investors, especially with its NYSE-listed shares showing recent gains in extended trading. Despite a year-to-date decline, analysts maintain a "moderate buy" rating with a significant projected upside. The company's strategic position in infection prevention, driven by recurring revenues and exposure to critical healthcare segments, makes it a relevant consideration for US investors.
Steris plc stock (IE00BFY8C754): solid earnings momentum and infection-control demand
Steris plc reported strong financial results for its latest quarter, driven by high demand for its infection prevention and sterilization products and services. The company's core business model focuses on assisting healthcare providers and life science companies in maintaining sterile environments through various segments like Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. Steris plc's shares on the NYSE reflect its defensive healthcare characteristics, with growth supported by recurring service revenues and demand for its specialized solutions in a regulated market.
Steris stock (IE00BFY8C754): earnings update and long-term hygiene demand
Steris plc reported solid quarterly results for fiscal Q4 and full year ended March 31, 2025, showing continued revenue growth driven by demand in medical sterilization and infection prevention due to aging populations and stricter control standards. The company's diverse portfolio across healthcare, applied sterilization technologies, and life sciences contributes to its recurring revenue model, making it an established player in the healthcare infrastructure market. Investors should monitor valuation, healthcare spending trends, and evolving regulations despite the strong demand drivers.
Steris plc stock (IE00BFY8C754): Revenue momentum and analyst targets stay in focus
Steris plc (IE00BFY8C754) is gaining investor attention due to its consistent revenue growth in the medical equipment and infection prevention sectors, alongside positive analyst price targets. The company's business model, heavily reliant on recurring revenue from consumables and service contracts, makes it a stable "defense-style" healthcare investment, less susceptible to economic downturns. Analysts have set an average price target significantly above its recent closing price, suggesting continued investor interest, though future performance will depend on upcoming earnings reports and guidance.
Q1 Earnings Highs And Lows: STERIS (NYSE:STE) Vs The Rest Of The Surgical Equipment & Consumables - Diversified Stocks
This article analyzes the Q1 2026 earnings performance of STERIS (NYSE:STE) and its peers in the surgical equipment & consumables - diversified industry. While STERIS's revenue was in line with expectations, it showed the weakest performance against estimates among its peers. The report also highlights the strong performance of Zimmer Biomet (NYSE:ZBH), BD (NYSE:BDX), Solventum (NYSE:SOLV), and CONMED (NYSE:CNMD), noting their revenue figures and market reactions.
Steris PLC stock outperforms competitors on strong trading day
This article reports that Steris PLC (STE) stock performed well, outperforming its competitors on a recent strong trading day. However, without the actual content of the article, specific details about the stock's performance or reasons for the outperformance cannot be provided.
Steris PLC stock outperforms competitors on strong trading day
This article reports that Steris PLC (STE) stock outperformed its competitors on a recent trading day. The stock recorded gains while major indices like the S&P 500 and Dow Jones Industrial Average experienced losses. This positive performance positioned Steris PLC favorably against its industry peers.
Is WM’s Sustainability-Focused COO Appointment Quietly Reshaping Its Long-Term Operating Strategy (WM)?
Waste Management recently appointed Tara Hemmer, formerly Chief Sustainability Officer, as Executive Vice President and Chief Operating Officer. This move integrates sustainability directly into daily operations, impacting the company's recycling and renewable energy agendas. While not immediately altering core investment catalysts and risks, this alignment is significant for investors observing how WM converts sustainability investments into earnings, particularly alongside the ongoing integration of WM Healthcare Solutions after the Stericycle acquisition.
STERIS plc stock (US8589121081): Institutional buying highlights infection-prevention specialist
STERIS plc (NYSE: STE) has gained attention after Dana Investment Advisors acquired a new position of 39,753 shares, with the stock trading near $260. The company, headquartered in Dublin, Ireland, specializes in infection prevention products and services for healthcare and life science sectors. Its business model combines capital equipment, consumables, and service contracts, providing recurring revenue streams in a regulatory-driven market.
Dana Investment Advisors Inc. Acquires 39,753 Shares of STERIS plc $STE
Dana Investment Advisors Inc. significantly increased its stake in STERIS plc (NYSE:STE) by 88.9% in the fourth quarter, adding 39,753 shares to now hold 84,465 shares valued at approximately $21.4 million. STERIS recently announced a quarterly dividend of $0.63 per share, payable on June 26th, and reported mixed quarterly earnings with EPS slightly below estimates but revenue matching expectations. The stock currently holds a "Moderate Buy" consensus rating from analysts with an average price target of $275.67.
Number of shareholders of STERIS plc (Ireland) – NYSE:STE
This article provides details on the number of shareholders for STERIS plc (Ireland) under the NYSE ticker STE. It mentions that the data is sourced from FactSet Research Systems Inc. and covers period value, change, and change percentage.
Steris PLC stock outperforms competitors despite losses on the day
Steris PLC (STE) shares fell 1.79% to $212.11 on Friday, breaking a three-day winning streak. Despite the decline, the stock's performance outpaced the broader market, as the S&P 500 Index dropped 1.24% and the Dow Jones Industrial Average fell 1.07%. The article highlights Steris's relative strength in a challenging trading session.
Steris plc stock (IE00BFY8C754): steady growth story after latest earnings
Steris plc has demonstrated steady growth in its latest quarterly report, with increased revenue and earnings, and its stock trading near recent highs. The company, a leading provider of infection prevention and sterilization products, benefits from a diversified business model including capital equipment sales and recurring revenue from services and consumables. This strategy, combined with its strong presence in North America, positions Steris as a resilient investment in the healthcare infrastructure sector.
How Investors May Respond To STERIS (STE) Record FY26 Results And US$1 Billion Buyback Plan
STERIS plc (STE) reported record full-year sales of US$5,935.9 million and net income of US$782.3 million for fiscal 2026, along with new fiscal 2027 guidance and a US$1.00 billion share repurchase authorization. This signals management's confidence in sustained demand for its infection prevention and sterilization products. The buyback reinforces the investment narrative of converting cash generation into per-share growth, while the company's long-term outlook projects US$7.0 billion revenue and US$1.0 billion earnings by 2029, with a fair value estimate of US$279.29.
New STERIS (STE) director Pierre Boulud files initial Form 3 ownership report
STERIS plc (STE) new director, Pierre Boulud, has filed an initial Form 3 ownership report with the SEC. This filing establishes his status as a board member and subjects any future holdings to SEC disclosure rules, but this specific report does not list any transactions or specific share amounts. The Form 3 clarifies that Boulud is not a ten percent owner and aims to enhance transparency regarding insider ownership at STERIS.
Steris bets big on Mentor with new $60M plant and U.S. consolidation plan
Steris plans to invest $60 million in a new sterility assurance plant in Mentor, Ohio, as part of a U.S. consolidation strategy. The company's manufacturing facilities are currently located at 9325 Pinecone Drive, Mentor, Ohio. This significant investment underscores Steris's commitment to the Mentor area.
Steris PLC stock outperforms competitors on strong trading day
Steris PLC (STE) shares rose 2.31% to $215.98 on Thursday, outperforming the broader market. This gain marked the stock's third consecutive day of increases, with the S&P 500 Index and Dow Jones Industrial Average also closing higher.
Steris plc stock (IE00BFY8C754): Shares up 1.41% to $230.46 on Jul 25
Steris plc stock rose 1.41% to $230.46 on July 25, 2025, driven by positive signals in the medical equipment sector. The company holds a Moderate Buy consensus rating with 28.32% upside potential and is considered a key player in infection prevention and sterilization. Its steady demand from aging populations and post-pandemic hygiene focus positions it well in the medical devices industry.
How Investors May Respond To STERIS (STE) Record FY26 Results And US$1 Billion Buyback Plan
STERIS plc reported strong fiscal 2026 results with record annual revenue of US$5,935.9 million and net income of US$782.3 million, alongside new fiscal 2027 guidance and a US$1.00 billion share repurchase authorization. This performance reinforces the investment narrative focusing on steady demand for infection prevention products. Investors will now assess how this buyback and continued growth prospects, especially against potential tariff and reimbursement pressures, will impact STERIS's long-term performance and fair value.
KeyBanc Maintains Steris PLC(STE.US) With Buy Rating, Cuts Target Price to $269
KeyBanc has reiterated its Buy rating on Steris PLC (STE.US) but has reduced its target price for the company to $269. This suggests the firm still sees value in Steris despite a revised valuation.
KeyBanc cuts STERIS stock price target on lower peer multiples
KeyBanc has reduced its price target for STERIS stock to $269 from $291, while maintaining an Overweight rating. This adjustment is due to lower peer multiples, despite STERIS's strong fiscal 2027 guidance and favorable financial health according to InvestingPro. The company's Q4 results were slightly below expectations for EPS but exceeded revenue forecasts.
Stephens Adjusts Price Target on STERIS to $270 From $300, Maintains Overweight Rating
Stephens has lowered its price target for STERIS (STE) shares to $270 from $300, while reiterating an Overweight rating on the stock. This adjustment comes alongside similar price target revisions from other firms like Jefferies, Piper Sandler, and KeyBanc. STERIS recently reported its Q4 2026 earnings, with adjusted earnings and revenue rising, and provided fiscal year 2027 adjusted EPS guidance.
Jefferies Adjusts Price Target on STERIS to $225 From $253, Maintains Hold Rating
Jefferies has lowered its price target for STERIS (STE) from $253 to $225, while maintaining a Hold rating on the stock. This adjustment comes alongside similar movements from other financial firms, with Piper Sandler also adjusting their price target to $270 from $300 and KeyBanc adjusting theirs to $269 from $291, though both maintained Overweight ratings. The changes follow recent Q4 2026 earnings reports and fiscal 2027 guidance from STERIS.
Needham Maintains Steris PLC(STE.US) With Hold Rating
Needham has reaffirmed its Hold rating on Steris PLC (STE.US). This indicates the firm's continued neutral outlook on the company's stock performance.
Higher Near-Term Revenue Forecasts and Expanding Margins Lift Steris' Fair Value Estimate
Morningstar analysts have increased their fair value estimate for Steris (STE) due to higher near-term revenue forecasts and expanding margins. The company's strategic acquisitions and expanded product portfolio position it as a key provider of sterilization products and services, particularly benefiting the growing ambulatory surgery centers and physicians’ offices. The updated forecast also considers a sensible share buyback plan and promising guidance for fiscal year 2027.
Transcript: Steris Q4 2026 Earnings Conference Call
Steris reported a strong Q4 and fiscal year 2026, with total revenue up 7% and 9% respectively, and adjusted EPS up 10% for the year, despite tariff impacts. The company projects 7% to 8% revenue growth for fiscal 2027 and authorized a new $1 billion share buyback program. Healthcare and Life Sciences segments performed well, and Steris plans strategic investments in facilities and technology to support future growth and efficiency.
Piper Sandler Maintains Steris PLC(STE.US) With Buy Rating, Maintains Target Price $300
Piper Sandler has reiterated its Buy rating for Steris PLC (STE.US), maintaining a target price of $300. This continued endorsement suggests the firm's confidence in the company's future performance. Financial analysts often issue such ratings to guide investors on potential stock movements.
Research Alert: CFRA Retains Buy Rating On Steris Plc
CFRA has reaffirmed its Buy rating on Steris Plc (STE), as reported by MT Newswires. This research alert also briefly mentions Unity Software's (U.US) fourth-quarter financial results, noting a 35% year-over-year revenue increase to $609 million, surpassing consensus estimates, despite the company reporting a quarterly loss of 66 cents per share.
STE Q4 Earnings & Revenues Miss, Stock Dips in Aftermarket Trading
STERIS plc (STE) reported its fourth-quarter fiscal 2026 earnings and revenues, with both figures missing Zacks Consensus Estimates. Despite broad-based segment growth and an improved gross margin, the stock declined in after-market trading due to investor concerns. The company provided a fiscal 2027 outlook, projecting revenue growth of 7-8% and adjusted diluted EPS in the range of $11.10-$11.30.
Steris anticipates 7%-8% revenue growth and $11.10-$11.30 EPS in fiscal 2027 as board authorizes $1B buyback
Steris plc projects 7-8% constant currency revenue growth and diluted EPS of $11.10-$11.30 for fiscal year 2027. This long-range outlook was provided during the company's investor day. Additionally, the company's board of directors authorized a new $1 billion share repurchase program.
Steris PLC stock outperforms competitors on strong trading day
Shares of Steris PLC (STE) increased by 4.46% to $210.85 on Tuesday, outperforming market indexes. This rise ended a three-day losing streak for the company's stock. The Dow Jones Industrial Average saw a slight gain, while the S&P 500 Index experienced a small decline.
State Street (STE) reports 5.1% stake in STERIS PLC in Schedule 13G
State Street Corporation has reported a beneficial ownership of 4,995,259 shares in STERIS PLC, which represents a 5.1% stake in the class as of March 31, 2026. This disclosure was made via a Schedule 13G filing, indicating a passive investment intent. The filing details shared voting power of over 3.1 million shares and shared dispositive power of nearly 5 million shares, held across various State Street-related entities for clients and investment-adviser/trustee purposes.
STERIS climbs after full-year results, new $1B buyback, and upbeat FY2027 outlook
STERIS (STE) shares rose 3.4% following its fiscal 2026 fourth-quarter and full-year update, which included a new $1 billion share repurchase program and an optimistic fiscal 2027 outlook, projecting adjusted EPS of $11.10–$11.30. The company reported fiscal 2026 revenue of $5.9 billion, a 9% year-over-year increase, and announced plans for a new sterility assurance manufacturing plant. Insider trading activity showed sales, while institutional investors had mixed movements, and Congress members made purchases of STE stock.
Earnings call transcript: STERIS Q4 2026 revenue beats, EPS misses slightly
STERIS plc reported mixed Q4 2026 results, with revenue of $1.6 billion exceeding forecasts but EPS of $2.83 slightly missing expectations. Despite solid year-over-year revenue growth and strategic expansions, the stock declined in premarket trading due to investor concerns over the EPS miss and continued cost pressures. The company provided optimistic FY 2027 guidance, anticipating revenue growth of 7-8% and EPS of $11.10-$11.30, while outlining capital allocation plans including a new $1 billion share buyback authorization.
Earnings call transcript: STERIS Q4 2026 revenue beats, EPS misses slightly
STERIS plc reported Q4 FY 2026 results with a slight miss on EPS at $2.83 against a forecast of $2.85, but beat revenue expectations with $1.6 billion, surpassing the anticipated $1.59 billion. Despite strong revenue growth and record financial performance for the fiscal year, the stock declined by 2.17% premarket due to investor concerns over the EPS miss and ongoing cost pressures. The company anticipates 7%-8% revenue growth and 9%-11% EPS growth for fiscal year 2027, driven by strategic initiatives and acquisitions, while managing tariff and inflation impacts.
Q4 2026 STERIS plc Earnings Call Transcript
STERIS plc reported a 7% increase in total revenue for Q4 2026, with 5% constant currency organic growth, marking a record year with 9% revenue and 10% adjusted EPS growth. The Healthcare segment showed strong performance, while the AST segment surpassed $1 billion in revenue. Despite a strong balance sheet, the company faced challenges with a decreased gross margin due to inflation and tariffs, an increased effective tax rate, and softness in AST due to severe weather.
Argus Adjusts Price Target on Stryker to $350 From $435, Maintains Buy Rating
Argus has adjusted its price target for Stryker (SYK) to $350 from $435, while maintaining a Buy rating on the stock. This news, published on May 12, 2026, reflects a revised outlook on the medical equipment and devices company. Stryker specializes in surgical equipment, neurotechnology, and orthopedic implants, with significant sales in the United States and Europe.
Rep. Gilbert Ray Cisneros, Jr. Acquires Shares of STERIS plc (NYSE:STE)
Representative Gilbert Ray Cisneros, Jr. recently purchased shares of STERIS plc (NYSE:STE) valued between $1,001 and $15,000. This transaction was part of several recent trades by the Representative, including purchases in Revvity, LPL Financial, FirstService, Wayfair, DoorDash, Sensata Technologies, and Veralto, and sales in Flex and SS&C Technologies. STERIS plc recently reported quarterly earnings that missed estimates but raised its fiscal 2027 guidance, reflecting confidence in its growth trajectory.
Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of STERIS plc (NYSE:STE)
Representative Gilbert Ray Cisneros, Jr. recently purchased between $1,001 and $15,000 worth of STERIS plc (NYSE:STE) shares on May 1st. This transaction comes as STERIS reported quarterly EPS of $2.83, slightly missing expectations, with revenue of $1.59 billion, increasing 6.7% year-over-year. The company also raised its FY 2027 EPS guidance and declared a quarterly dividend of $0.63 per share.
Steris 4Q Rev $1.6B >STE
Steris reported its fourth-quarter revenue of $1.6 billion. This exceeds analyst expectations. The company's stock symbol is STE.
Research Alert: Steris Closes Fiscal 2026 With Solid Growth And Initiates Fy 27 Guidance
This article announces that Steris closed its fiscal year 2026 with strong growth. The company also initiated its guidance for fiscal year 2027.
STERIS Fiscal Q4 Adjusted Earnings, Revenue Rise; Issues Fiscal 2027 Adjusted EPS Guidance
STERIS (STE) reported an increase in adjusted earnings and revenue for its fiscal Q4. The company also provided adjusted EPS guidance for fiscal year 2027. The article mentions Unity Software's Q4 earnings as well, noting a 35% revenue increase year-over-year to $609 million, exceeding consensus estimates, despite a quarterly loss of 66 cents per share.
Steris 4Q Adj EPS $2.83 >STE
Steris reported its fourth-quarter adjusted earnings per share of $2.83. This news pertains to the company's financial performance.
STERIS plc reports results for the quarter ended March 31 - Earnings Summary
STERIS plc has released its earnings summary for the quarter that concluded on March 31. The report contains financial results for the specified period.
